Minnesota Legislators Target Private Equity’s Grip on Autism Therapy Amid Profiteering Concerns
St. Paul, MN – In a significant move that signals a growing national scrutiny of private equity’s influence on healthcare, two prominent Minnesota state senators have announced plans to introduce legislation aimed at regulating investment firms operating within the autism therapy sector. The initiative, spearheaded by Democratic-Farmer-Labor (DFL) Senators Zaynab Mohamed of Minneapolis and Scott Dibble, also of Minneapolis, comes in direct response to a recent, scathing investigation by The 74 Million that exposed rampant profiteering and questionable practices within the burgeoning Applied Behavior Analysis (ABA) industry.
Senator Mohamed minced no words, stating, "This report is outrageous. The idea that Wall Street investors are exploiting these programs for profit is infuriating." Her sentiments were echoed by Senator Dibble, who has previously championed similar transparency measures in other healthcare sectors. Their proposed laws seek to mandate transparent ownership reporting for autism services centers and empower the state to scrutinize and potentially exclude entities whose business models are perceived to compromise the quality of care for vulnerable children. This legislative push highlights a broader ethical debate about the commodification of essential healthcare services and the impact of profit-driven motives on patient well-being, particularly in specialized fields like autism therapy.
The Catalyst: An Unsettling Investigation by The 74 Million
The urgency behind the Minnesota senators’ legislative efforts stems directly from a comprehensive investigation published by The 74 Million, an independent journalism organization focusing on education. The report, titled "Private Equity Is Cashing In On Autism Therapy. Children Are Paying The Price," meticulously detailed how, over the past decade, private equity firms have systematically acquired hundreds of "mom-and-pop" autism therapy centers across the nation, including Minnesota, consolidating them into vast, lucrative networks. These firms, operating with remarkably limited oversight, have significantly reshaped the landscape of autism care, transforming it into a fertile ground for investment returns.
The financial implications are staggering. According to The 74 Million‘s analysis, nationwide Medicaid reimbursements for ABA therapy skyrocketed from a mere $400 million in 2019 to nearly $2 billion by 2024. This dramatic increase coincides precisely with the period of aggressive private equity expansion into the sector. Further data from U.S. Centers for Medicare and Medicaid records, scrutinized by the investigation, revealed that private equity firms now own almost half of the 50 companies with the highest claims, accounting for a staggering $3.1 billion out of the almost $7 billion billed during the investigation’s six-year window. These figures paint a clear picture of a sector rapidly dominated by financial interests, where the potential for profit appears to outpace concerns for patient outcomes.
The Controversial Nature of Applied Behavior Analysis (ABA)
Beyond the financial exploitation, The 74 Million‘s reporting delved into the efficacy and ethical considerations surrounding Applied Behavior Analysis itself. While ABA has become the dominant and most widely reimbursed autism therapy nationwide, the investigation built upon previous reports questioning its "weak evidence base." ABA, often applied to autistic children as young as two years old for up to 40 hours a week, is a behavioral conditioning treatment designed to "extinguish" autistic traits through a system of rewards and punishments.
However, the efficacy of ABA, particularly its long-term impact and ethical implications, has been a contentious subject within the autistic community and among some researchers. Recent research, cited by The 74 Million, has indicated a troubling correlation between experiencing ABA intervention and heightened rates of Post-Traumatic Stress Disorder (PTSD) and psychiatric hospitalizations among autistic individuals. Critics argue that forcing autistic individuals to suppress natural behaviors can be traumatizing, leading to internalized shame and mental health challenges, rather than fostering genuine development and acceptance. The treatment’s historical roots and its focus on making autistic individuals "pass" as neurotypical have drawn considerable criticism, especially from self-advocates who view it as attempting to "cure" autism rather than supporting autistic individuals to thrive as they are. The ethical dilemma is compounded when the widespread adoption of such a therapy is driven more by lucrative reimbursement models than by a universally accepted standard of best practice or patient-centered care.
Minnesota: A Magnet for Private Equity Investment
Minnesota, like a handful of other states that have proactively worked to make services accessible to as many families with disabled children as possible, has inadvertently become an attractive and profitable market for large players in the autism therapy industry. As private equity firms entered the picture, a common business strategy involved moving out of states with lower Medicaid reimbursement rates and into those with more generous benefits, effectively chasing the highest profit margins. This phenomenon has created a landscape where the availability and quality of care can be dictated more by state-specific financial incentives than by an equitable distribution of necessary services.
The state’s commitment to supporting families with disabled children, while laudable, has inadvertently opened the door for private equity firms to capitalize on a robust funding environment. This dynamic underscores a critical challenge for policymakers: how to ensure access to vital services without creating an environment ripe for exploitation by entities whose primary allegiance is to their shareholders, not their patients.
Legislative Proposals: Demanding Transparency and Accountability
Senators Mohamed and Dibble are now seeking to fundamentally alter this dynamic. Their proposed legislation focuses on two key pillars: transparent reporting of ownership and the power to regulate business models that prioritize profit over patient welfare. They argue that as the "One Big Beautiful Bill Act" threatens to slash Medicaid spending, states have an even greater imperative to ensure that existing funds are utilized effectively and ethically to sustain children’s benefits.
Senator Dibble, drawing on his experience with similar legislative battles, articulated the frustration stemming from the current lack of transparency. Last year, he authored a bill (SF 2972) mandating disclosure of nursing home and assisted living facilities bought by for-profit companies, though it ultimately did not pass into law. He notes that the impact of private equity on applied behavior analysis mirrors the detrimental effects observed in other healthcare industries. A recent investigation by state healthcare monitors in Minnesota, for instance, found that 79% of complaints about abuse and neglect in long-term care facilities involved for-profit companies. When patient care suffers, the current opacity regarding a company’s true ownership makes it incredibly difficult to hold anyone accountable.
Dibble passionately conveyed the need for accountability: "It’s not enough to have a P.O. box in New Jersey. I think we’re entitled to know — this particular entity, what else do they own, and how well have they provided services?" He drew a compelling analogy to other regulated industries: "Before someone can come in and purchase a liquor license, they need to prove that they’re an outstanding citizen who hasn’t participated in any shady practices and they can be entrusted with the public trust that a publicly issued license entails." This comparison highlights the senators’ belief that healthcare providers, particularly those serving vulnerable populations and funded by public dollars, should be held to an equally rigorous, if not higher, standard of public trust and transparency.
Furthermore, the proposed legislation is expected to include provisions requiring providers to allocate a certain percentage of the Medicaid reimbursements they receive directly to patient care. This measure aims to curb excessive administrative costs and profit extraction, ensuring that public funds are primarily directed towards the services for which they are intended. "This kind of aggressive super-sized profit motive is totally inappropriate in these settings," Dibble asserted, "because it incentivizes behaviors that don’t support the public’s interest and good use of public dollars."
Broader Context: Medicaid Fraud, Waste, and Systemic Profiteering
The legislative push in Minnesota arrives amidst a national backdrop of heightened concerns regarding fraud, waste, and abuse within Medicaid reimbursement for autism therapy. Over the last year, scandals have erupted across the country, drawing significant attention to the vulnerabilities of the system. Minnesota itself has previously drawn the ire of the Trump administration, which controversially cited alleged Medicaid abuse perpetrated by immigrants as a justification for a violent Immigration and Customs Enforcement (ICE) incursion into the Twin Cities.
In February, the Department of Government Efficiency released a massive 275 million-record Medicaid dataset, ostensibly to aid in rooting out waste, fraud, and abuse. However, The 74 Million‘s analysis of this very data uncovered a different, more systemic problem: not primarily individual acts of fraud, but rather "unchecked profiteering and lax state and federal oversight of ABA, and rapid acquisition of its providers by private equity." This finding shifts the narrative from individual bad actors to a structural issue, where the system itself, through its lack of robust regulation, enables exploitation.
Private equity firms typically operate by acquiring privately held companies that boast steady revenue streams. Their business model often involves maximizing cash extraction in the short term, frequently through aggressive cost-cutting measures, increased patient quotas, and reduced staff-to-patient ratios, before selling off the company, often leaving it burdened with significant debt. This cycle, as Senator Dibble noted, has been mirrored in various other healthcare sectors, from emergency rooms to dental clinics and nursing homes, often with devastating consequences for patient care and the long-term viability of the services.
Implications for Patients, Families, and the Future of Care
The implications of unchecked private equity involvement in autism therapy extend far beyond financial spreadsheets. When a private equity firm has paid its investors the generated cash and subsequently exits, the remaining debt can often lead to bankruptcy or the inability of healthcare providers to continue offering services. This leaves families, who have often invested significant emotional and financial resources into their children’s care, scrambling to find new providers, disrupting crucial therapeutic continuity for autistic children who often thrive on routine and stability. The emotional toll on these families, forced to navigate an already complex system while dealing with the fallout of corporate decisions, can be immense.
Critics emphasize that the lack of clarity regarding ownership not only hinders accountability but also obscures the true motivations driving healthcare decisions. When the primary incentive is profit, there is an inherent risk that the quality of patient care, the ethical delivery of therapy, and the long-term well-being of autistic individuals will be compromised. The fundamental question raised by these legislative efforts is whether healthcare, especially for vulnerable populations, can truly thrive when subject to the same aggressive profit-maximization strategies applied to other industries.
The Minnesota senators’ proposed legislation represents a critical step towards addressing these systemic issues. It seeks to reassert public interest and ethical considerations at the forefront of autism therapy provision. Success in Minnesota could serve as a powerful precedent, inspiring similar legislative actions in other states and potentially catalyzing a broader national discussion about the ethical boundaries of private investment in essential healthcare services. The battle lines are drawn between profit motives and patient welfare, and Minnesota appears poised to lead the charge in demanding greater transparency and accountability for those entrusted with the care of its most vulnerable citizens.
